Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Si-Yun Liu"'
Publikováno v:
BMC Medical Imaging, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is highly malignant and has a poor prognosis due to the lack of effective therapeutic targets. Androgen receptor (AR) has been investigated as a possible therapeutic target. This study quantita
Externí odkaz:
https://doaj.org/article/a411688865e8409f9c7133c8ecd03e8b
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Both the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging system for perihilar cholangiocarcinoma (pCCA) had the same definition for T2a and T2b. But the value of this classification as prognostic fact
Externí odkaz:
https://doaj.org/article/d3e6ed75c6ae482db1b8cd03a1de97de
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeIt is challenging for traditional CT signs to predict invasiveness of pancreatic solid pseudopapillary neoplasm (pSPN). We aim to develop and evaluate CT-based radiomics signature to preoperatively predict invasive behavior in pSPN.MethodsEigh
Externí odkaz:
https://doaj.org/article/2eb5a01f66ed4f29a55f4d85a7235909
Autor:
Bin Song, Yuan-Yi Zhu, Fu-Yu Li, Jun Zhang, Hao-Yu Zheng, Jian Zhao, Wei Zhang, Li Xu, Si-Yun Liu
Publikováno v:
Journal of Magnetic Resonance Imaging. 55:787-802
BACKGROUND Cholangiocarcinoma is a type of hepatobiliary tumor. For perihilar cholangiocarcinoma (pCCA), patients who experience early recurrence (ER) have a poor prognosis. Preoperative accurate prediction of postoperative ER can avoid unnecessary o
Autor:
Si-Yun Liu, Jie Jiang, Duan Hui, Bing He, Li Wu, Heng Luo, Dan Han, Xiaojie Xie, Xing-Wen Zhang, Yi Zhao, Yi Wu, Jian-You Chen
Publikováno v:
Lung Cancer. 157:30-39
We aimed to explore the feasibility of 2D and 3D radiomics signature based on the unenhanced computed tomography (CT) images to predict BRCA1-associated protein 1 (BAP1) gene mutation status for malignant pleural mesothelioma (MPM) patients.74 patien
Autor:
Ke-Pu Du, Wen-Peng Huang, Si-Yun Liu, Yun-Jin Chen, Li-Ming Li, Xiao-Nan Liu, Yi-Jing Han, Yue Zhou, Chen-Chen Liu, Jian-Bo Gao
Publikováno v:
World journal of gastroenterology. 28(31)
The biological behavior of carcinoma of the esophagogastric junction (CEGJ) is different from that of gastric or esophageal cancer. Differentiating squamous cell carcinoma of the esophagogastric junction (SCCEG) from adenocarcinoma of the esophagogas
Publikováno v:
Contrast Media & Molecular Imaging, Vol 2020 (2020)
Contrast Media & Molecular Imaging
Contrast Media & Molecular Imaging
The most common mesenchymal tumors are gastrointestinal stromal tumors (GISTs), which have malignant potential and can occur anywhere along the gastrointestinal system. Imaging methods are important and indispensable of GISTs in diagnosis, risk stagi
Autor:
Yi Yuan, Xiao-li Chen, Zhen-lin Li, Guang-wen Chen, Hao Liu, Yi-Sha Liu, Ming-hui Pang, Si-yun Liu, Hong Pu, Hang Li
Publikováno v:
European radiology. 32(8)
To investigate the diagnostic performance of the apparent diffusion coefficient (ADC) derived from intratumoral and peritumoral zones for assessing pathologic prognostic factors in rectal cancer.One hundred forty-six patients with rectal cancer who u
Autor:
Xiaohong Ma, Si-Yun Liu, Kun Chen, Zhong-Wei Chen, Shuang Wang, Long-Bin Hu, Dengfeng Li, Yong-Tao Mi, Zhiyuan Wu, Xinming Zhao
Publikováno v:
World Journal of Gastroenterology
BACKGROUND Hepatocellular carcinoma (HCC) ranks second in terms of cancer mortality worldwide. Molecular magnetic resonance imaging (MRI) targeting HCC biomarkers such as alpha-fetoprotein (AFP) or glypican-3 (GPC3) offers new strategies to enhance s
Autor:
Xiao-Hong Ma, Kun Chen, Shuang Wang, Si-Yun Liu, Deng-Feng Li, Yong-Tao Mi, Zhi-Yuan Wu, Chun-Feng Qu, Xin-Ming Zhao
Publikováno v:
World journal of gastrointestinal oncology. 14(4)
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. HCC-targeted magnetic resonance imaging (MRI) is an effective noninvasive diagnostic method that involves targeting clinically-related HCC biomarkers, such as alp